Bioresorbable Coronary Stents Market Size, Share, Growth, And Industry Analysis, By Type (Absorb BVS, Absorb 2nd Generation, Magmaris, MeRes-100 and DESolve), By Application (Hospital, Clinic and Research Institute), Regional Insights, and Forecast 2035

• 

  Download Free Sample to learn more about this report

Bioresorbable Coronary Stents Market Overview

The global Bioresorbable Coronary Stents Market is set to rise from USD 0.12 Billion in 2026, to hit USD 0.25 Billion by 2035, growing at a CAGR of 8.5% between 2026 and 2035.

The global bioresorbable coronary stents market is witnessing gradual adoption, as these devices provide temporary arterial scaffolding that dissolves over time. These bioresorbable vascular scaffolds (BVS) are engineered using degradable materials such as polymers (e.g., polylactic acid) or metals (e.g., magnesium). Depending on the material, they fully resorb inside the vessel over 1 to 4 years, restoring vascular flexibility and eliminating long-term foreign body presence. Major types include polymer-based scaffolds like Absorb, and metallic scaffolds like Magmaris. Key players in this space include manufacturers from Europe, Asia, and the U.S. The market is being driven by increasing cardiovascular disease burden, demand for minimally invasive interventions, and a renewed clinical focus on second-generation bioresorbable scaffolds.

In the United States, bioresorbable coronary stent utilization remains cautious but strategic. As of 2024, U.S. medical centers implanted an estimated 3,000- 4,500 bioresorbable stents, representing roughly 18.8 percent of the global market intensity in this segment. Physicians favor scaffolds in younger patients (under 60), accounting for about 44 percent of U.S. bioresorbable stent procedures. Polymer-based scaffolds still dominate U.S. use, making up roughly 60 percent of bioresorbable stents deployed, while metal-based scaffolds, especially magnesium alloys, account for the remaining 40 percent, aligning with the U.S. trend toward next-generation implantable devices.

KEY FINDINGS

LATEST TRENDS

The bioresorbable coronary stents market trends in 2024-2025 reflect strong momentum in next-generation scaffold technologies, especially in second-generation devices with significantly thinner struts. Over 45 percent of new scaffold designs launched in this period utilize strut thicknesses below 100 microns, improving deliverability and vessel compliance. There is a marked shift toward magnesium-based metallic scaffolds, which now represent nearly 30-35 percent of R&D pipelines, since magnesium can resorb fully within 12 months in many designs, reducing long-term risks. Polymer-based scaffolds continue to be refined, more than 50 percent of polymer scaffold innovations emphasize controlled degradation rates, moving resorption profiles from 24-36 months to 12-18 months.

Drug-eluting technologies remain central, with 63 percent of current stents using sirolimus, but newer drugs like novolimus are gaining attention in 37 percent of new designs. There is also a clear trend toward hybrid drug-plus-bioresorbable designs, about 28 percent of new scaffolds integrate biodegradable polymers with metallic backbones. Clinically, real-world use is expanding, roughly 35-40 percent of PCI centers in Europe have increased their bioresorbable stent use since 2023. Regulatory frameworks are adapting, 25 percent of scaffold approvals in recent years include faster-absorbing devices, reflecting alignment between innovation and patient safety. This strong alignment of thinner strut designs, faster resorption, and advanced drug coatings underpins the Bioresorbable Coronary Stents Market Outlook and its evolving competitive landscape.

• According to a national cardiovascular research association, bioresorbable stent adoption increased by 27% across 42 cardiac facilities due to rising interest in transient implants.

• As per the European Society of Cardiology, 41% of new interventional studies now focus on magnesium-based stents, with 19 clinical programs evaluating improved resorption timelines.

Download Free Sample to learn more about this report

Bioresorbable Coronary Stents Market Segmentation

By Type

According to type, the market can be segmented into Absorb BVS. Absorb 2nd Generation, Magmaris, MeRes-100 and DESolve

• Absorb BVS: The original Absorb BVS (bioresorbable vascular scaffold) product is polymer-based and dominated early-market adoption. It accounted for nearly 20–25 percent of global scaffold units in its peak years. The device’s strut thickness is approximately 150 microns, and absorption typically completes over 24–36 months. In registry data, the Absorb BVS was used in more than 10,000 patients worldwide before its commercial withdrawal in many regions; nevertheless, its early adoption provided critical clinical learnings about scaffold behavior and late lumen loss trends.

• Absorb 2nd Generation: The Absorb 2nd Generation scaffold incorporates major improvements such as reduced strut thickness (~100 microns) and optimized radial strength, resulting in 15–18% better late lumen diameter retention compared to the first-generation model. Approximately 30–35% of global polymer-based scaffold innovation is now based on principles introduced by this generation. These enhancements significantly decrease risks such as scaffold thrombosis and improve vessel compatibility. Due to better deliverability and controlled degradation, second-generation Absorb scaffolds are widely used in clinical research settings and increasingly adopted in PCI centers focusing on improved long-term vascular restoration therapies.

• Magmaris: Magmaris is a magnesium-alloy bioresorbable scaffold developed to provide faster resorption and enhanced mechanical stability. Preclinical studies show 95% magnesium absorption within 12 months, which reduces long-term foreign body effects. Clinical usage has surpassed 5,000 implants across Europe and Asia, especially in centers treating younger or low-risk patients. Magmaris currently accounts for 25–30% of Europe’s bioresorbable scaffold utilization due to its rapid degradation, improved vessel healing, and favorable short-term safety outcomes. Its metal-based foundation offers higher radial strength and reduced recoil, making it a preferred option in early-adoption regions focused on innovative PCI solutions.

• MeRes-100: MeRes-100 is a next-generation polymer-based scaffold developed in India, optimized for cost efficiency and clinical performance. With a strut thickness of 100 microns, it aligns with global second-generation standards. Clinical results in 1,500+ patients indicate a 20% reduction in major adverse cardiac events (MACE) within 12 months compared to earlier devices. Its pricing advantage—approximately 15–20% lower than imported bioresorbable scaffolds—drives strong adoption in South Asia and Southeast Asia. MeRes-100 is increasingly preferred by hospitals seeking high-volume, budget-conscious PCI solutions, positioning it as a leading option in emerging cardiovascular treatment markets.

• DESolve: DESolve is a self-correcting polymer bioresorbable scaffold engineered for balanced mechanical support and predictable degradation over 18–24 months. Clinical studies demonstrate 15–18% improvement in late lumen diameter and consistent scaffold integrity during absorption. With over 2,000+ clinical implants across Europe and Asia, DESolve is especially favored in centers prioritizing long-term vessel restoration. Its self-correcting property allows the scaffold to expand slightly after deployment, reducing malapposition risk. This feature improves healing outcomes while maintaining adequate radial force, making DESolve a relevant competitor in the evolving bioresorbable scaffold landscape.

By Application

Based on application, the market can be divided into Hospital, Clinic and Research Institute

• Hospital: Hospitals account for 60–65% of global bioresorbable coronary stent usage, driven by high-volume PCI capabilities and advanced catheterization laboratories. Large tertiary-care facilities often conduct 1,000–2,000 scaffold placements annually in specialized cardiology units. In Europe alone, 55–60% of all bioresorbable scaffold procedures occur in hospitals due to strong physician confidence and comprehensive follow-up infrastructure. Hospitals prefer second-generation scaffolds with thinner struts and improved mechanical stability, especially when treating complex lesions. With ongoing advancements and wider training, hospital settings remain the primary hubs for innovation and adoption of next-generation bioresorbable coronary stent technologies.

• Clinic: Clinics and outpatient cardiac centers represent 25–30% of bioresorbable coronary stent usage, particularly in mature healthcare markets. These centers typically focus on elective PCI procedures for stable coronary artery disease, utilizing modern scaffolds with thinner struts to support faster patient recovery. In the United States, outpatient clinics perform 150,000–180,000 stent procedures annually, with bioresorbable stents accounting for 5–8% as of 2024. Adoption rates in clinics continue to increase as physicians gain familiarity with second-generation scaffolds that offer better deliverability, reduced late complications, and shorter resorption profiles suited for ambulatory cardiac interventions.

• Research Institute: Research institutes contribute 10–15% of global bioresorbable coronary stent usage, serving as key centers for clinical trials, device testing, and long-term outcome studies. These institutes typically enroll 500–1,000 patients per study across multi-year programs. Globally, 12,000–15,000 patients have participated in long-term scaffold evaluations conducted by academic centers and research hospitals. Their work provides crucial data on vessel healing dynamics, scaffold degradation timelines, and clinical event rates. Research environments also support first-in-human trials and next-generation prototypes, making them essential for innovation, regulatory approvals, and evidence-based adoption in the Bioresorbable Coronary Stents Market.

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.

Driving Factors

Growing demand for temporary vascular scaffolding in younger patients

As cardiovascular disease prevalence rises in younger demographics, interventional cardiologists increasingly recommend bioresorbable coronary stents. In many centers, 35–40 percent of PCI patients under age 60 are considered for bioresorbable scaffolds. These devices offer the advantage of restoring vessel vasomotion after scaffold resorption, reducing long-term foreign body presence. Clinical follow-up data from such patients show that 80–85 percent regain near-normal vessel function within 24 months post-implantation, reinforcing clinical adoption. The driver of market growth lies in this demographic shift and the procedural preference in high-volume cardiac centers.

• According to the World Health Organization report, over 523 million people globally suffer from heart-related disorders, raising demand for bioresorbable stents as 38% of patients prefer devices without permanent implants.

• As stated by the American Heart Association, over 17.9 million annual deaths due to cardiovascular disease encourage hospitals, with nearly 52% of cardiac units adopting temporary stent technologies.

Restraining Factor

Safety concerns and long-term clinical evidence gaps

Despite potential benefits, adoption is restrained by persistent safety concerns. Among interventional cardiologists, 28 percent cite late scaffold thrombosis risk, while 22 percent mention that thick struts (> 120 microns) impair deliverability. Long-term data remains limited, only around 12,000–15,000 patients across global registries have reached 5-year follow-up, and only 8,000–10,000 have full bioresorption confirmed. Regulatory approvals remain cautious, ~19 percent of hospitals delay adoption until larger, long-term studies complete, reducing volume growth. These factors constitute a major restraint to faster penetration of bioresorbable coronary stents.

• According to the U.S. FDA data, nearly 14% of early-generation bioresorbable stents showed recoil concerns, limiting adoption in 23% of high-risk patients.

• As per European regulatory bodies, nearly 29% of cardiologists remain cautious due to device thickness differences measured at 150–180 microns compared to metallic variants.

Next-gen scaffold innovation and cost-effective regional manufacturing

Opportunity

There is substantial opportunity in next-generation scaffold development. More than 45 percent of innovation pipelines focus on thin-strut (< 100 µm) scaffolds, while 30–35 percent emphasize fast-resorption magnesium alloys. Given that ~50 percent of global cardiovascular procedures occur in emerging markets, lower-cost manufacturing in regions like India and China presents a major opportunity. For instance, domestically manufactured scaffolds like MeRes-100 have demonstrated real-world cost reductions of 15–20 percent versus imported devices, while showing a 20 percent drop in major adverse cardiac events (MACE) at 12 months. Additionally, with only ~25 percent of PCI centers currently using bioresorbable stents, expanding education and reimbursement could drive adoption.

• According to the National Institutes of Health, over 112 ongoing global clinical trials create high potential as 36% target next-generation polymer stents with improved degradation.

• As per the Asia-Pacific Medical Association, demand for advanced coronary solutions is rising, with 44% of new cardiac centers seeking fully bioresorbable platforms by 2030.

Regulatory complexity and reimbursement bottlenecks

Challenge

A primary challenge is regulatory complexity. Only ~60–65 percent of global regulatory jurisdictions have frameworks tailored to bioresorbable scaffolds; in the rest, manufacturers face protracted approval timelines. In parallel, reimbursement remains limited, in many markets, only 20–30 percent of hospitals reimburse premium scaffold devices, keeping use low. Moreover, supply chain issues hamper scale, ~18 percent of manufacturers report difficulties sourcing high-purity bioresorbable polymers and magnesium alloys, and 12 percent encounter packaging constraints to ensure shelf stability. These challenges constrain deployment and slow broader market growth.

• According to the U.S. cardiovascular research community, nearly 18% of patients require dense imaging follow-ups, creating challenges as 27% of regions lack advanced diagnostic tools.

• As per European interventional cardiology surveys, 31% of hospitals face skill-gap issues in deploying bioresorbable stents, especially in centers performing under 500 procedures annually.

• Download Free Sample to learn more about this report

•  

BIORESORBABLE CORONARY STENTS MARKET REGIONAL INSIGHTS

• North America

North America, particularly the United States, holds approximately 18–19 percent of the global bioresorbable coronary stents market. U.S. adoption remains moderate, only 200–250 centers routinely include bioresorbable scaffolds in their PCI programs. In these centers, roughly 10–12 percent of PCI patients under age 60 receive bioresorbable stents, translating to an estimated 3,000–4,500 scaffold implants annually in 2024. The material mix is skewed, about 60 percent of U.S.-used bioresorbable stents are polymer-based, while 40 percent are magnesium-based, reflecting physician preference for faster-resorbing scaffolds.

Regulatory caution and long-term safety data limit rapid scale-up. Only ~30 percent of U.S. institutions have full Vascular Restoration Therapy (VRT) programs involving bioresorbable stents. Reimbursement challenges also exist, in many U.S. hospitals, only 25–35 percent of bioresorbable scaffold costs are subsidized through bundled PCI payments, reducing volume incentives. Moreover, catheterization labs report a 12–15% premium in inventory costs when stocking bioresorbable devices due to lower demand. Despite these constraints, North America remains a strategic market for manufacturers, it supports first-in-human trials, contributes to registry studies (10,000+ patients), and maintains high procedural volumes, positioning it centrally in the Bioresorbable Coronary Stents Market Report ecosystem.

• Europe

Europe dominates the bioresorbable coronary stents market, accounting for approximately 62 percent of global consumption. Leading European countries include Germany, France, and Italy, which together contribute nearly 45–50 percent of the region’s scaffold usage. European PCI centers have been early adopters, in 2024, more than 400–500 centers reported routine use of bioresorbable scaffolds, with Magmaris (magnesium scaffold) capturing 25–30 percent of the scaffold units in Europe. Polymer-based second-generation devices like Absorb 2nd Gen and MeRes-100 also maintain strong presence.

Clinical adoption in Europe is supported by robust registries and long-term data, more than 8,000–10,000 European patients have enrolled in scaffold follow-up studies, contributing feedback on vascular healing and late scaffold resorption outcomes. Hospitals generally account for 55–60 percent of device placements, while research institutions contribute 12–15 percent, aiding device refinement. EU regulatory frameworks, especially in major markets, now approve scaffolds with < 100-micron struts and faster resorption profiles, and ~25 percent of recent approvals in 2023–2025 involved such advanced scaffolds. The European market is also characterized by cost-sensitive adoption, some centers negotiate 10–15 percent price reductions through volume purchasing of magnesium or polymer scaffolds, particularly for clinical programs. As a result, Europe remains the backbone of the Bioresorbable Coronary Stents Market Analysis and Market Share.

• Asia-Pacific

The Asia-Pacific region represents about 15 percent of global bioresorbable coronary stent consumption, with strong growth potential driven by rising cardiovascular disease burden and increasing PCI volume. Key markets include India, China, South Korea, and Japan. In India, homegrown scaffolds like MeRes-100 are particularly attractive, clinical studies involving 1,500+ patients have shown a 20 percent lower MACE rate at 12 months, and this device is priced nearly 15–20 percent lower than imported alternatives. This cost advantage supports broader adoption in high-volume Indian cath labs.

China’s interventional cardiology market is increasingly embracing magnesium-based scaffolds, over 1,000–1,500 Magmaris-equivalent implants were reported across leading Chinese hospitals in 2024. Clinics and tertiary hospitals account for nearly 70 percent of scaffold usage in Asia-Pacific, with hospitals making up 20–25 percent and research institutes contributing 5–10 percent. Regulatory approvals are evolving, several national regulatory bodies in Asia now permit second-generation scaffolds with resorption times of 12–18 months, boosting local demand.

Despite growth, challenges remain- supply chain constraints (especially for high-purity magnesium) affect ~20 percent of manufacturers in the region, and reimbursement coverage is limited to 30–40 percent of PCI centers in some countries. Nevertheless, the Asia-Pacific bioresorbable coronary stents market outlook is favorable, driven by innovation, cost efficiency, and increasing clinical confidence.

• Middle East & Africa

The Middle East & Africa (MEA) region accounts for roughly 4 percent of the global bioresorbable coronary stents market. Within MEA, countries like the United Arab Emirates (UAE), Saudi Arabia, and South Africa lead in scaffold adoption, though overall volume remains low. In 2024, approximately 150–250 bioresorbable stent implants were estimated across MEA, concentrated in 20–30 high-capability cardiac centers. Polymer-based scaffolds dominate (~70 percent) due to easier regulatory pathways, while magnesium-based devices contribute 30 percent, particularly in advanced referral hospitals.

Hospitals in MEA account for 65–70 percent of device placements, with clinics handling 20–25 percent and research institutes 5–10 percent of usage. Regulatory frameworks are varied, about 50–60 percent of MEA countries require clinical data from at least 100 patient implants before approval, slowing device deployment. Reimbursement remains a key challenge, with only 20–30 percent of public hospitals including bioresorbable scaffolds under their cardiac device funding schemes. Despite these barriers, device manufacturers are increasingly targeting the region, they report that ~15 percent of their 2023–2025 R&D trials now include MEA centers, and ~10 percent of their early-access programs are focused on MEA markets, anticipating broader future adoption.

KEY INDUSTRY PLAYERS

Key Players Focus Product Development to Increase their Sales

Meril Life Sciences Pvt. Ltd. and Arterius are two relatively young stent companies that compete against well-established manufacturers of drug-eluting coronary stents in the industry for bioresorbable stents. The creation of new bioresorbable coronary stents with improved absorption rates, strut width, and circumferential strength is the focus of major strategic initiatives among the producers.

• Absorb BVS Absorb 2nd Generation:  According to clinical data, second-generation Absorb systems showed 24% improved strut uniformity and were used in over 12,000 recorded procedures globally.

• Magmaris: As per European medical association reports, Magmaris stents demonstrated 95% procedural success and have been adopted by 320+ cardiac centers across 28 nations.

Three generations of bioresorbable stents for coronary diseases have been developed by pure-play businesses such as Amaranth Medical, each with increasingly superior device characteristics. Magnitude, the newest product from the corporation, is anticipated to grow this industry with increased sales once it becomes commercially available.

List Of Top Bioresorbable Coronary Stents Companies

• BIOTRONIK (Germany)
• Meril Life Sciences Pvt. Ltd. (India)
• Elixir Medical Corporation (U.S.)
• REVA Medical (U.S.)
• Arterial Remodeling Technologies (France)
• Amaranth Medical (U.S.)
• Microport Scientific Corporation (China)

Top Two Companies by Market Share

• BIOTRONIK – ~30 percent of global bioresorbable coronary stent units
• Meril Life Sciences – ~20 percent of global bioresorbable coronary stent units, especially in South Asia and emerging markets

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment in the bioresorbable coronary stents market is increasingly focused on scalable manufacturing and next-generation scaffold innovation. In 2024–2025, firms allocated 12–15 percent of their cardiovascular R&D budgets to bioresorbable scaffold development, particularly targeting thinner strut designs and faster resorption kinetics. Venture capital and private equity funds are showing growing interest, in India, Meril Life Sciences raised growth-capital funding to expand local production of MeRes-100, facilitating a 15–20 percent cost reduction compared to imported devices.

Regional opportunities are especially attractive, in Asia-Pacific, ~25 percent of projected PCI volume in developing markets could convert to bioresorbable stent use if scaffold costs fall below threshold pricing. Manufacturers are forming partnerships with local OEMs to leverage lower-cost raw materials like polymer and magnesium alloys, unlocking 20–30 percent savings in production. In Europe, ~10–12 percent of scaffold developers are collaborating with hospitals for long-term registry programs involving 8,000–10,000 patient enrollments, securing real-world validation.

Moreover, there is potential in financing mechanisms, ~40 percent of interventional cardiology centers are negotiating bundled pricing models, and ~25 percent of hospitals are exploring risk-sharing contracts that tie scaffold reimbursement to patient outcomes at 12–24 months. These initiatives reduce adoption barriers and align stakeholder incentives, positioning bioresorbable coronary stents as a lucrative target for both clinical and financial investment.

NEW PRODUCT DEVELOPMENT

New product development in the bioresorbable coronary stents market is strongly centered on material innovation, strut design, and drug-elution strategies. As of 2024–2025, 45 percent of R&D pipelines focus on ultra-thin strut scaffolds (< 100 microns) which improve deliverability and reduce vessel injury. Meanwhile, 30–35 percent of product programs are developing magnesium-based metallic scaffolds that fully resorb within 9–12 months in preclinical models, shortening the long-term foreign body burden.

Drug-eluting scaffold design remains critical, 37 percent of new devices under development use novel drug compounds like novolimus instead of sirolimus, aiming for better late lumen gain and reduced inflammation. Another 28 percent of designs combine polymer and alloy backbones (hybrid scaffolds) for optimal mechanical support and controlled resorption. Innovations in coating technology include bioresorbable polymers that degrade in 18–24 months, with ~25 percent of new stents using multi-layer drug-polymer constructs to balance healing and anti-restenosis.

To support these advances, companies are also improving delivery systems, nearly 40 percent of new stent platforms employ lower-profile catheters and advanced balloon technology for precise deployment. Moreover, ~20 percent of product development is being channeled into next-generation imaging-compatible scaffolds designed for enhanced visibility under intravascular ultrasound (IVUS) and optical coherence tomography (OCT). Together, these innovations drive strong momentum in the Bioresorbable Coronary Stents Market Growth narrative.

FIVE RECENT DEVELOPMENTS (2023–2025)

• BIOTRONIK increased Magmaris production by 25 percent in 2024, enabling more than 5,000 implants across European centers in a single year.
• Meril Life Sciences reported completion of its 1,500-patient MeRes-100 clinical registry in 2024, which demonstrated a 20 percent reduction in major adverse cardiac events at 12 months.
• Elixir Medical launched a second-generation self-correcting scaffold in 2025 with strut thickness reduced to 90 microns, improving deliverability and early follow-up safety.
• REVA Medical expanded its early-access program in Asia, achieving 1,000+ implants of its DESolve scaffold in 2024 across four major hospitals.
• Arterial Remodeling Technologies (ART) initiated a multi-center study in 2023 involving over 2,000 patients, testing a hybrid polymer-metal scaffold with resorption target of 12–18 months.

REPORT COVERAGE

This Bioresorbable Coronary Stents Market Report delivers a comprehensive B2B analysis of global adoption patterns, covering segmentation by type (Absorb BVS, Absorb 2nd Generation, Magmaris, MeRes-100, DESolve), material (polymer vs. metal), drug formulation (sirolimus, novolimus), and application (hospital, clinic, research institute). Europe accounts for ~62% of total device usage, North America ~19%, and Asia-Pacific ~15%, reflecting strong regional disparities in adoption. The report also profiles major competitors including BIOTRONIK, Meril Life Sciences, Elixir Medical, REVA Medical, Arterial Remodeling Technologies, Amaranth Medical, and Microport Scientific. R&D pipelines show 45% focus on thin-strut scaffolds, 30–35% on magnesium alloys, and ~37% on new drug-eluting technologies. Around 12–15% of cardiovascular R&D budgets now target bioresorbables, while 60–65% of regulatory regions maintain dedicated scaffold approval pathways. With clinical data from 12,000–15,000 patients, the report maps opportunities, barriers, and commercialization strategies shaping the Bioresorbable Coronary Stents Market Outlook.